COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT02194985
Previous Study | Return to List | Next Study

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02194985
Recruitment Status : Completed
First Posted : July 21, 2014
Last Update Posted : August 6, 2020
Information provided by (Responsible Party):
Amicus Therapeutics

Brief Summary:

This is an open-label extension study intended to provide continued treatment with migalastat HCl for subjects with Fabry disease who completed treatment of a previous migalastat HCl monotherapy study.

The study will assess the long-term safety and effectiveness of migalastat HCl in subjects with Fabry disease who completed migalastat HCl treatment in a previous study.

Condition or disease Intervention/treatment Phase
Fabry Disease Drug: migalastat HCl 150 mg Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Actual Study Start Date : October 2014
Actual Primary Completion Date : October 23, 2019
Actual Study Completion Date : October 23, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: migalastat HCl 150 mg
Migalastat HCl is a capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on days between migalastat HCl.
Drug: migalastat HCl 150 mg
Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.
Other Name: AT1001

Primary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: up to 5 years ]
    non-serious AEs, serious AEs., possible suicidality related AEs

  2. Withdrawal due to AEs [ Time Frame: up to 5 years ]
    including non-serious and serious AEs

  3. Vital signs and body weight - change in baseline in vital signs and body weight [ Time Frame: up to 5 years ]
    blood pressure and heart rate

  4. Change from baseline in laboratory parameters [ Time Frame: up to 5 years ]
    hematology, chemistry, and urinalysis

  5. Change from baseline in electrocardiogram (ECG) [ Time Frame: up to 5 years ]
    12-lead ECG

  6. Change from baseline in echocardiography [ Time Frame: up to 5 years ]
    echocardiography ultrasound

Secondary Outcome Measures :
  1. Estimated glomerular filtration rate (eGFR) [ Time Frame: up to 5 years ]
    based on the Modification of Diet in Renal Disease (MDRD) equation and CKD-EPI equation

  2. Measurement of left ventricular mass (LVM) and left ventricular mass index (LVMi) [ Time Frame: up to 5 years ]
    as measured by echocardiography

  3. Ejection fraction [ Time Frame: up to 5 years ]
    as measured by echocardiography

  4. Fractional shortening [ Time Frame: up to 5 years ]
    as assessed by echocardiography

  5. Measurement of LV internal dimension (LVIDd and LVIDs) and wall thickness [ Time Frame: up to 5 years ]
    as assessed by echocardiography

  6. Measurement of white blood cell (WBC) α-Gal A activity [ Time Frame: up to 5 years ]
    enzyme responsible for breaking down GL-3

  7. Measurement of subject reported Quality of Life [ Time Frame: up to 5 years ]
    as assessed by the Short Form - 36 Survey (SF-36)

  8. Measurement of 24-hour urine protein [ Time Frame: up to 5 years ]
  9. Plasma lyso-Gb3 [ Time Frame: up to 5 years ]
    biomarker shown to be elevated in Fabry subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject had completed treatment in a previous study of migalastat HCl
  • Age 18 years or older
  • Male and female participant agrees to use protocol identified acceptable contraception
  • Subject is willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI)

Exclusion Criteria:

  • Subjects last available estimated glomerular filtration rate (eGFR) in the previous study was <30 mL/min/1.73m2; unless there is measured GFR available within 3 months of Baseline Visit (Visit 1), which is >30 mL/min/1.73m2
  • Subject has undergone, or is scheduled to undergo kidney transplantation or is currently on dialysis
  • Subject has a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Visit 1
  • Subject has clinically significant unstable cardiac disease in the opinion of the investigator (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)
  • Subject has a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (e.g., miglustat, miglitol)
  • Subject requires treatment with Glyset® (miglitol) or Zavesca® (miglustat)
  • Subjects with severe or unsuitable concomitant medical condition
  • Subjects with clinically significant abnormal laboratory value(s) and clinically significant electrocardiogram (ECG) findings at baseline

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02194985

Show Show 29 study locations
Sponsors and Collaborators
Amicus Therapeutics
Layout table for investigator information
Study Director: Medical Monitor, Clinical Research, MD Amicus Therapeutics, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Amicus Therapeutics Identifier: NCT02194985    
Other Study ID Numbers: AT1001-042
First Posted: July 21, 2014    Key Record Dates
Last Update Posted: August 6, 2020
Last Verified: August 2020
Keywords provided by Amicus Therapeutics:
Fabry disease
Lysosomal storage disease
migalastat HCl
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders